The safety of tenofovir-emtricitabine for HIV pre-exposure prophylaxis (PrEP) in individuals with active hepatitis B

The safety of tenofovir-emtricitabine for HIV pre-exposure prophylaxis (PrEP) in individuals with active hepatitis B

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. Background: Pre-exposure prophylaxis (PrEP) with daily oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) prevents HIV infection. The safety and feasibility of HIV PrEP in the setting of hepatitis B virus (HBV) infection w...

Full description

Saved in:

Bibliographic Details
Main Authors:	Marc M. Solomon, Mauro Schechter, Albert Y. Liu, Vanessa M. McManhan, Juan V. Guanira, Robert J. Hance, Suwat Chariyalertsak, Kenneth H. Mayer, Robert M. Grant, Linda Gail Bekker, Susan Buchbinder, Martin Casapia, Esper Kallas, Javier Lama, Orlando Montoya, Valdiléa Veloso
Format:	Journal
Published:	2018
Subjects:	Medicine
Online Access:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84959166158&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/56244
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	Chiang Mai University

Similar Items

The safety of tenofovir-emtricitabine for HIV pre-exposure prophylaxis (PrEP) in individuals with active hepatitis B
by: Solomon M., et al.
Published: (2017)

Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men
by: Peter L. Anderson, et al.
Published: (2018)

Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men
by: Anderson P., et al.
Published: (2017)

Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis
by: Marc M. Solomon, et al.
Published: (2018)

Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis
by: Marc M. Solomon, et al.
Published: (2018)

Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine
by: David V. Glidden, et al.
Published: (2018)

Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis
by: Solomon M.M., et al.
Published: (2014)

Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project
by: Matthew A. Spinelli, et al.
Published: (2019)

Patterns and correlates of PrEP drug detection among MSM and transgender women in the global iPrEx study
by: Albert Liu, et al.
Published: (2018)

Patterns and correlates of PrEP drug detection among MSM and transgender women in the global iPrEx study
by: Albert Liu, et al.
Published: (2018)

International sexual partnerships may be shaped by sexual histories and socioeconomic status
by: Hong Ha M. Truong, et al.
Published: (2018)

International sexual partnerships may be shaped by sexual histories and socioeconomic status
by: Hong Ha M. Truong, et al.
Published: (2018)

Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial
by: Marc M. Solomon, et al.
Published: (2018)

Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial
by: Marc M. Solomon, et al.
Published: (2018)

International sexual partnerships may be shaped by sexual histories and socioeconomic status
by: Truong H., et al.
Published: (2017)

Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial
by: Kathleen Mulligan, et al.
Published: (2018)

Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial
by: Kathleen Mulligan, et al.
Published: (2018)

Brief Report: Routine Use of Oral PrEP in a Phase 2 Rectal Microbicide Study of Tenofovir Reduced-Glycerin 1% Gel (MTN-017)
by: Albert Y. Liu, et al.
Published: (2019)

Brief Report: Recovery of Bone Mineral Density after Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis
by: David V. Glidden, et al.
Published: (2018)

Brief Report: Recovery of Bone Mineral Density after Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis
by: David V. Glidden, et al.
Published: (2018)

Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men
by: Alex Carballo-Diéguez, et al.
Published: (2018)

Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men
by: Alex Carballo-Diéguez, et al.
Published: (2018)

HIV pre-exposure prophylaxis in transgender women: A subgroup analysis of the iPrEx trial
by: Madeline B. Deutsch, et al.
Published: (2018)

HIV pre-exposure prophylaxis in transgender women: A subgroup analysis of the iPrEx trial
by: Madeline B. Deutsch, et al.
Published: (2018)

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial
by: Avihingsanon A.
Published: (2023)

Strong correlation between concentrations of tenofovir (TFV) emtricitabine (FTC) in hair and TFV diphosphate and FTC triphosphate in dried blood spots in the iPrEx open label extension: Implications for pre-exposure prophylaxis adherence monitoring
by: Monica Gandhi, et al.
Published: (2018)

Strong correlation between concentrations of tenofovir (TFV) emtricitabine (FTC) in hair and TFV diphosphate and FTC triphosphate in dried blood spots in the iPrEx open label extension: Implications for pre-exposure prophylaxis adherence monitoring
by: Monica Gandhi, et al.
Published: (2018)

Double oral administration of emtricitabine/tenofovir prior to virus exposure protects against highly pathogenic simian/human immunodeficiency virus infection in macaques
by: Nakasone, T., et al.
Published: (2016)

Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test
by: Monica Gandhi, et al.
Published: (2019)

A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: The TARGET study
by: Cressey T., et al.
Published: (2017)

A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: The TARGET study
by: Tim R. Cressey, et al.
Published: (2018)

A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: The TARGET study
by: Tim R. Cressey, et al.
Published: (2018)

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial
by: Molina J., et al.
Published: (2017)

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials
by: Yeon Sook Kim, et al.
Published: (2020)

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial
by: Jean Michel Molina, et al.
Published: (2018)

Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial
by: Patawee Boontanondha, et al.
Published: (2020)

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials
by: Yeon Sook Kim, et al.
Published: (2020)

Slow Uptake of PrEP: Behavioral Predictors and the Influence of Price on PrEP Uptake Among MSM with a High Interest in PrEP
by: Mart van Dijk, et al.
Published: (2022)

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial
by: Aditya H. Gaur, et al.
Published: (2022)

Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials
by: Avihingsanon A.
Published: (2023)